Clinical trial
A Post- Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System
NCT03908125 is registered in ClinicalTrials.gov with Senseonics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Post- Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System
- Lead sponsor
- Senseonics, Inc.
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- March 19, 2019
- Completion date
- February 1, 2024
- Enrollment
- 273 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.